Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 23

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 23
---
                                             
 our Initial Public Offering, there has been a precipitous drop in the market values of companies formed through mergers involving   
 special purpose acquisition companies. Accordingly, securities of companies such as ours may be more volatile than other securities 
 and may involve special risks.                                                                                                      |

<div align='center'>4</div>

| ● | securities of companies                                                                                                            
 formed through mergers with special purpose acquisition companies such as ours may experience a material decline in price relative 
 to the share price of the special purpose acquisition companies prior to the merger.                                               |

| ● | our                                                                                           
 Public Warrants will become exercisable for our common stock, which would increase the number 
 of shares eligible for future resale in the public market and would result in dilution to     
 our stockholders.                                                                             |

| ● | the                                                                                               
 issuance of shares of our Common Stock upon conversion or exercise of our outstanding Series      
 A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C Warrants          
 and other securities that we may issue in future financing transactions may result in substantial 
 dilution to our stockholders.                                                                     |

| ● | there                                                                                         
 is no public market for Offered Common Warrants or the Pre-Funded Warrants to purchase shares 
 of our common stock being offered by us in this offering.                                     |

Implications of Being an Emerging Growth Company and a Smaller Reporting Company We are an “emerging growth company” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements